Overt signs of toxicity to dogs and cats of dietary deoxynivalenol

Studies were conducted to determine the dietary amounts of deoxynivalenol (DON; vomitoxin) in dog and cat food that are required to produce overt signs of toxicity (e.g., vomiting or reduced food intake). Wheat naturally contaminated with 37 mg of DON/kg was used to manufacture pet foods containing 0, 1, 2, 4, 6, 8, and 10 mg of DON/kg. Deoxynivalenol concentration in pet food following manufacture was unchanged, indicating that the toxin was stable during conventional extrusion processing. Dogs previously fed DON-contaminated food were able to preferentially select uncontaminated food. Dogs not previously exposed to DON-contaminated food consumed equal quantities of contaminated and uncontaminated food. There was no effect of 6 mg of DON/kg on dog food digestibility. Food intake of dogs was significantly reduced by DON concentrations greater than 4.5 +/- 1.7 mg/kg, and DON greater than 7.7 +/- 1.1 mg/kg reduced cat food intake. Vomiting by dogs and cats was commonly observed at the 8 and 10 mg DON levels.     

Effect of the interval between feeding and drug administration on oral ampicillin absorption in dogs

Eight dogs of various breeds received single oral doses of 20 mg/kg bodyweight ampicillin at four different time intervals relative to feeding a meal. In treatment A the dogs were fasted for 12 hours before and after ampicillin administration. In treatment B the dogs received ampicillin immediately after, in treatment C one hour before and in treatment D two hours after the meal. Each dog received these treatments during a period of feeding dry and canned dog food according to an 8 × 8 Latin square design. Blood samples were taken at specified time intervals after drug administration by jugular venepuncture. Antibiotic concentrations in plasma were determined by microbiological assay. Non-compartmental pharmacokinetic parameters were calculated from the individual concentration-time curves and were compared by non-parametric statistic tests between treatments and types of food. With both dry and canned food ampicillin absorption was impaired when the drug and food were given at the same time (treatment B) as compared to the absorption in fasting dogs (treatment A and C). On dry food, drug absorption was also decreased in treatment D. It is recommended for clinical purposes to give ampicillin to fasted dogs, and to wait at least one hour before feeding. After a meal (dry food) waiting two hours until drug administration is not sufficient to avoid impaired ampicillin absorption.     

Effects of compounded metronidazole and metronidazole benzoate oral suspensions on food intake in healthy chinchillas (Chinchilla lanigera)

BackgroundThe administration of metronidazole in chinchillas remains controversial and some sources raise concerns regarding drug-induced anorexia or hyporexia. Therefore, the objective of this study was to evaluate if the oral administration of oral metronidazole has a significant effect on food intake in clinically healthy chinchillas, and if drug-induced reduction of food intake differs between metronidazole and metronidazole benzoate as well as between different concentrations of metronidazole benzoate suspensions.MethodsIn a series of randomized, blinded, crossover experiments, the effects of oral administration of metronidaole at 20 mg/kg was evaluated following q12h (for 3 days, n = 12) or q24h (for 5 days, n = 9) dosing using two different drug compounding protocols.ResultsFollowing administration of metronidazole, food intake was significantly reduced within 24 hours of drug administration, regardless of drug formulation type, compounding protocol, or drug concentration. Variation in metronidazole-induced food intake reduction differed widely between individual chinchillas, with a reduction of >50% of food intake reported in 50% of the animals following q12h administration, and 33% of animals after q24h administration of metronidazole. The reduction in food intake was self-limiting and return to normal food intake occurred after discontinuation of metronidazole administration. Neurological adverse effects were observed in one animal following q12h administration.Conclusions and clinical relevanceThe oral administration of metronidazole and metronidazole benzoate at published dosages can result in a marked reduction in food intake, and therefore, this drug should be used cautiously in chinchillas and food intake carefully monitored.     

Opioid modulation of feeding and drinking in fowls

1. D-ala2-methionine enkephalinamide (DME), the stable analogue of met-enkephalin (an opioid agonist), stimulated food intake of immature hens in the first 30 min after intracerebroventricular injection (2 and 8 micrograms/kg), but had no effect on either food or water intake when injected intravenously (15 and 60 micrograms/kg). 2. Naloxone (an opioid antagonist) had no effect on food intake after either intracerebroventricular (50 and 200 micrograms/kg) or intravenous (1 and 4 mg/kg) injection, but inhibited water intake in the second 30 min after intravenous injection. 3. Water intake was not measured after the intracerebroventricular injections of DME and naloxone. 4. Both feeding and drinking were inhibited in a dose-related way in the 7 h after intramuscular injection of nalmefene (0.2, 0.4, 0.8 and 1.6 mg/kg), a more potent and longer-lasting antagonist than naloxone. 5. These data are compared with published results from similar work with birds and mammals. It is concluded that central release of endogenous opioids may reinforce both feeding and drinking in fowls, but whereas opioid blockage affects feeding more than drinking in pigeons and quail, the opposite appears to be the case in fowls.     

Influence of dirlotapide, a microsomal triglyceride transfer protein inhibitor, on the digestibility of a dry expanded diet in adult dogs

The objectives of this study were to evaluate the effects of dirlotapide, a microsomal triglyceride transfer protein inhibitor, on apparent nutrient digestibility of an expanded dry dog food, on defecation frequency and fecal consistency. Eighteen beagles were randomized to either placebo ( n  = 6) or dirlotapide ( n  = 12). Testing was divided into a 21-day adaptation phase (days −21 to −1) and a 35-day treatment (digestibility testing) phase (days 0–35). During the treatment phase, dogs were administered oral dirlotapide (0.3 mg/kg) or placebo (0.06 mL/kg) once daily. For digestibility testing, feces were collected over two periods for 7 days each starting on days −9 and 28. All dogs were fed a commercial adult dog food throughout the study. Food intake was adjusted to maintain body weight during adaptation, followed by pair-feeding placebo dogs the amount of food ingested by the dirlotapide dogs during the treatment period. Dogs in both groups had reduced food intake and lost similar amounts of body weight during treatment. Dogs receiving 0.3 mg dirlotapide/kg once daily had a small but significant ( P  = 0.018) decrease (6.16 ± 2.22%, mean ± SD) in crude fat digestibility compared with the placebo-treated food-restricted dogs, but no difference in crude protein, dry matter, or energy digestibility was observed. Fecal consistency and volume and defecation frequency were similar between groups. Dirlotapide effectively reduced appetite and energy intake without affecting nutrient digestibility, except for a minimal decrease in fat digestibility.     

The safety of dirlotapide in dogs

The safety of dirlotapide in dogs was evaluated in two studies with parallel designs. In an acute tolerance study, 24 beagles (six dogs per treatment) were treated orally once daily for 14 days with placebo or dirlotapide at 2.5, 5.0, or 10.0 mg/kg/day. In a margin-of-safety study, 38 overweight, neutered beagles were treated orally once daily for 3 months with dirlotapide at doses up to 0.5 mg/kg/day (six dogs), 1.5 mg/kg/day (12 dogs) and 2.5 mg/kg/day (six dogs). Control dogs received placebo at 0.3 mL/kg/day (10 dogs) and 0.5 mL/kg/day (four dogs). Results were similar for both studies, and no serious adverse events were observed. Dirlotapide was clinically well-tolerated in dogs at dosages up to 10 mg/kg/day for 14 days and 2.5 mg/kg/day for 3 months. Dirlotapide produced the expected decrease in food intake and body weight (up to 20–40%) without ill effects. Clinical, pathologic, and histopathologic findings were reversible and consistent with suppression of food intake and rapid weight loss produced by elevated dirlotapide dosages. In both studies, sporadic emesis and loose stools were observed in both placebo and dirlotapide-treated dogs. Incidence of emesis generally increased with dose and decreased with treatment time. Elevations in hepatic transaminase activity were seen in dogs treated with more than 1.5 mg/kg dirlotapide daily, but were not associated with clinical signs or microscopic evidence of hepatic degeneration or necrosis.     

Effects of dietary cottonseed meal, with and without iron treatment, on laying hens

1. The effects of feeding a screw-press expelled cottonseed meal (CSM) to laying hens at dietary concentrations of up to 300 g/kg, were studied over a 10 week period. 2. The overall performance of hens fed on a 75g CSM/kg diet was not significantly different from controls but a 300g CSM/kg diet, containing 255 mg free gossypol/kg and 87 mg cyclopropenoid fatty acids (CPFA)/kg and giving daily intakes per hen of 26.2 mg free gossypol and 9.0 mg CPFA, significantly reduced food intake (P less than 0.01) and egg production (P less than 0.01). The 150g CSM/kg diet (daily intakes of 14.6 mg free gossypol and 4.8 mg CPFA per hen) did not produce adverse effects initially but egg production was slightly depressed towards the end of the experimental period. 3. Treatment of the CSM with a solution of ferrous sulphate hepta-hydrate for inclusion in a 300g CSM/kg diet (100 mg/kg supplemental dietary iron) further reduced food intake (P less than 0.05) and egg production (P less than 0.05). 4. Storage of eggs at warm temperatures for up to 1 month did not lead to discolourations of any kind in the CSM diet groups, but resulted in yolk mottling, a condition reduced by treatment of the CSM with iron. 5. Storage of eggs at cold temperatures for 3 months resulted in brown yolk discolouration and the initial stages of pink albumen discolouration in the 300g CSM/kg diet group; the brown yolk discolouration was reduced by treatment of the CSM with iron.     

Dietary L-carnitine increases plasma leptin concentrations of gestating sows fed one meal per day

Thirty-four sows (parity=1.8; BW=206 kg) were used to determine the influence of L-carnitine and/or chromium tripicolinate on plasma leptin concentrations of gestating sows fed one meal daily. Treatments were arranged in a 2 x 2 factorial with main effects of carnitine (0 or 50 ppm) and chromium (0 or 200 ppb). Diets were fed for approximately 167 days (through one gestation, the following lactation, the interval from weaning to estrus, and 28 days into the following gestation) prior to blood collection. Leptin concentration was determined in plasma that was collected at feeding, every 15 min for the first 3h after feeding, and at 6, 9, 15, 20, and 24h after feeding. Sows fed diets containing carnitine had greater (P<0.02) overall mean plasma leptin concentrations and greater (P<0.05) leptin concentrations at 2.25, 3, 6, 15, 20, and 24h after feeding compared to sows fed either the control diet or the diet containing chromium. Leptin concentrations of sows fed diets containing carnitine also were greater (P<0.05) than control sows at 2.5 and 2.75 h postprandial and greater than (P<0.05) sows fed diets with both carnitine and chromium at 6h after feeding. Chromium had no effect (P>0.10) on plasma leptin concentration. These results suggest that dietary carnitine, but not chromium, increases circulating leptin in gestating sows fed one meal per day. These results may help to explain the improvements in reproductive function previously observed from feeding sows diets containing carnitine.     

Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles

A novel, transdermal fentanyl solution (TFS) was developed that delivers sustained concentrations of fentanyl for days following a single application. The pharmacokinetics following a single topical dose was examined. Eighteen adult Beagle dogs were divided into three groups of six dogs (3M, 3F). Each group was administered a single dose of 1.3 (25), 2.6 (50), or 5.2 mg/kg (100 μL/kg) of TFS. The dose was applied to the clipped, ventral abdominal skin using a 1-mL tuberculin syringe. Immediately following dosing, collars were placed on each dog through 72 h to prevent direct licking of the application site. Serial jugular venous blood samples were collected at 0 (predosing), 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 240, 336, 408, and 504 h after dosing and assayed for plasma fentanyl concentration. Fentanyl was rapidly detected following application with a mean absorption lag time (t(lag) ) of 0.333 h in the 1.3 mg/kg group and 0 in the other two groups. The mean C(max) increased with dose and were 2.28, 2.67, and 4.71 ng/mL in the 1.3, 2.6 and 5.2 mg/kg dose groups, respectively. Mean terminal half-lives were 53.7, 69.6, and 103 h in the 1.3, 2.6, and 5.2 mg/kg dose groups, respectively. The mean AUC(0-LLOQ) from lowest to highest dose groups were 157, 268, and 645 ng·h/mL and were dose proportional with a R(2) value of 0.9818. Adverse reactions were limited to the highest dose group and included sedation (four of six dogs) and decreased food and water intake (one dog). A dose of 2.6 mg/kg (50 μL/kg) is proposed for further development studies based on the lack of adverse events that were observed compared to the 5.2 mg/kg group and a more rapid onset of action and longer duration of action compared to the 1.3 mg/kg group.     

A diet lower in digestible carbohydrate results in lower postprandial glucose concentrations compared with a traditional canine diabetes diet and an adult maintenance diet in healthy dogs

The aim of this study was to compare the effects of three diets with varying macronutrient and fibre contents on postprandial plasma glucose, triglyceride, free fatty acid, and insulin concentrations over a 12 h period in 12 healthy neutered lean dogs. Each diet was fed to each dog for 3 weeks in a three-period cross-over study. Plasma analyte concentrations were measured prior to and after a meal at the end of the third week of each period. Postprandial glucose concentrations for the moderate carbohydrate and fibre diet were 0.4-0.7 mmol/L (8-12 mg/dL) lower than for both higher carbohydrate diets (p≤0.02). Postprandial glucose, insulin, and triglyceride concentrations in some dogs did not return to baseline by 12 h after feeding of each of the three diets. These results indicate that the moderate carbohydrate and fibre diet warrants evaluation in diabetic dogs. Variables should be measured over at least 12 h after feeding to fully evaluate postprandial dietary effects on these analytes.     

A high-protein, high-fiber diet designed for weight loss improves satiety in dogs

BACKGROUND: Weight-loss programs for dogs are often hampered by increased begging and scavenging behavior that ensues when food intake is restricted. HYPOTHESIS: A diet formulated to contain a high content of both protein and fiber is more satiating than diets that contain only high fiber or high protein. ANIMALS: Six entire female adult dogs (2 Shetland Sheepdogs, 2 Brittany Spaniels, 2 Labrador Retrievers) participated in the satiety studies; 105 adult female dogs of various breeds and ages were used for the palatability studies. METHODS: Three diets (high protein [103 g/1,000 kcal] high fiber [60 g/1,000 kcal] [HPHF]; high protein [104 g/1,000 kcal] moderate fiber [35 g/1,000 kcal] [HP]; moderate protein [86 g/1,000 kcal] high fiber [87 g/1,000 kcal] [HF]) were tested. Voluntary food intake was measured in 5 sequential crossover studies, and palatability was assessed with food preference tests. RESULTS: Protein digestibility was significantly lower for HF (mean +/- SD; 77.7% +/- 2.52%) than for both HPHF (81.1% +/- 0.96%) and HP (81.1% +/- 1.65%) (P < .001). Short-term food intake (food ingested when offered for 15 minutes every hour for 4 hours) was lower for HPHF than for both HP and HF (P = .038). Medium-term intake (food ingested when offered 3 hours after first meal) was lower for both HPHF (27 +/- 22.2 kcal/kg(0.73)) and HF (41 +/- 6.8 kcal/kg(0.73)) than for HP (57 +/- 18.8 kcal/kg(0.73)) (P = .041). Voluntary food intake 3 hours after feeding a restricted meal (25% daily maintenance energy requirements) was significantly lower on the HPHF diet than on either the HP (-51%, P = .0051) or HF (-47%, P = .014) diets. However, there was no significant difference between the energy intake on the HP and HF diets (7%, P = .37). The HPHF and HP diets had equivalent palatability, and both were more palatable than the HF diet (P < .001). CONCLUSIONS AND CLINICAL IMPORTANCE: The HPHF diet had a satiating effect as evidenced by reduced voluntary intake compared with HP and HF diets, and has the potential to lead to greater compliance in weight-loss programs.     

Diurnal variations of serum leptin in dogs: effects of fasting and re-feeding

Leptin is a protein synthesized and secreted primarily by adipocytes, and plays a key role in the regulation of energy balance. We have reported that serum leptin is elevated in obese dogs. In the present study, we examined diurnal variations of serum leptin in the dog, with special references to feeding and fasting cycles. Four male beagles were accustomed to feed once a day at 10:00 h, and blood samples were taken every 3 h for 24-36 h. Serum leptin concentration showed clear diurnal variations, being lowest before food intake (2.3+/-0.5 ng/mL) at 09:00 h, and highest (10.5+/-2.4 ng/mL) at 18:00 h. Such diurnal variations disappeared when the dogs were fasted. Serum insulin also showed diurnal variation with higher levels at 12:00-15:00 h. When insulin or glucose was injected in the fasted dogs to mimic the post-prandial insulin rise, serum leptin concentration was significantly increased in 4-8 h, but in both cases to a lesser extents than those after food intake. The results indicate that serum leptin concentrations change diurnally in association with feeding-fasting cycles in the dog, partially due to changes in insulin secretion.     

Biologic activity of dirlotapide, a novel microsomal triglyceride transfer protein inhibitor, for weight loss in obese dogs

Dirlotapide is a novel microsomal triglyceride transfer protein inhibitor intended for the treatment and management of obesity in dogs. The biologic effects of dirlotapide, weight loss, decreased food intake, increased fecal fat, decreased serum cholesterol, and body composition, were evaluated in a controlled, blinded study. Sixteen obese beagles were randomized to treatment with placebo ( n  = 4) or dirlotapide ( n  = 12) following a 2-week acclimation period in which baseline data were collected. The dirlotapide dose, adjusted to produce weight loss for 3 months and then stabilize body weight for 1 month (weight management), produced a significant difference (expressed as a percentage of baselines) in weekly weight loss, food intake, fecal fat, serum cholesterol concentration, and body composition (measured by dual energy X-ray absorptiometry) compared with placebo treatment ( P  < 0.05). The initial dirlotapide dosage of 0.5 mg/kg (10 times the initial label dose) resulted in a high rate of weight loss (3.3% weekly) and anorexia, emesis, and loose stools for some dogs. A 25% dose reduction (mean dosage: 0.36 mg/kg) followed by biweekly 25% dose adjustments based on individual weight loss, produced 1–2% weekly weight loss and total weight loss of 18.8% in 12 weeks at a final mean dosage of 0.41 mg/kg (range: 0.15–0.60); a dosage range of 0.10–0.34 mg/kg stabilized body weight. Body weight changes for placebo-treated dogs were −0.8% to +0.9% weekly; total weight gain during the weight loss phase was 10.6%. No apparent change in food intake, percentage of fecal fat, and serum cholesterol was observed in the placebo group. Food intake and body weight increased when dirlotapide was discontinued. Dirlotapide produced weight loss by both reducing appetite (about 90% of the weight loss activity) and by increasing fecal fat excretion (about 10% of the weight loss activity).     

The effect of mixing and changing the order of feeding oats and chopped alfalfa to horses on: glycaemic and insulinaemic responses, and breath hydrogen and methane production

The aim of this study was to investigate the effects of feeding oats alone before or after feeding chopped alfalfa or, in admixture with the alfalfa on the glycaemic and insulinaemic responses of horses as well as post-prandial breath hydrogen and methane excretion. Horses were fed in a randomized order, chopped alfalfa as a source of dietary fibre and unprocessed oats as a source of starch. Chopped alfalfa intake was adjusted to a crude fibre intake of 0.5 g/kg bodyweight (BW) per meal and the oats intake was adjusted to a starch intake of 2 g/kg BW per meal. The feeds were offered in three different ways: (i) alfalfa followed by oats (A/O), (ii) oats followed by alfalfa (O/A) or (iii) a mixture of alfalfa and oats (A + O). Oats alone were used as a control. Blood and breath were collected after the test meal was fed at the end of a 11.5-h overnight fast following a 10-day acclimatization period. The highest glycaemic and insulinaemic responses were measured when the A/O and O/A diets orders were fed, whereas most hydrogen was produced after feeding oats alone. It was concluded that adding alfalfa chaff to a meal of oats prolonged the pre-caecal digestion of starch, but there was no evidence for any effect on pre-caecal starch digestibility.     

Changes in gallbladder volume in healthy dogs after food was withheld for 12 hours followed by ingestion of a meal or a meal containing erythromycin

OBJECTIVE: To assess the influence of meal ingestion and orally administered erythromycin on gallbladder volume in dogs. ANIMALS: 22 healthy dogs. PROCEDURES: Ultrasonographically determined gallbladder dimensions in unsedated dogs were used to calculate volume. Measurements were recorded after food was withheld for 12 hours (time 0) and 15, 30, 45, 60, 90, and 120 minutes after a 100-g meal without (n = 22) or with erythromycin (1.0 mg/kg [7], 2.5 mg/kg [7], and both dosages [8]). Gallbladder ejection fraction represented the percentage of volume change from time 0. Intraday and interday coefficients of variation determined operator repeatability and physiologic variation. RESULTS: We did not detect significant differences in gallbladder volume per unit of body weight between treatments at time 0 or in ejection fraction percentage within or between treatments. Median time 0 gallbladder volume was 0.6 mL/kg (range, 0.4 to 1.9) but was > 1.0 mL/kg in 3 of 22 (14%) dogs and or= 25% with at least 1 treatment, but 2 dogs with a gallbladder volume or= 25% were typical. No treatment consistently induced greater gallbladder contraction. Dogs with a gallbladder volume > 1.0 mL/kg and ejection fraction < 25% may require a combined meal and erythromycin protocol.     

Evaluation of once daily treatment with cyclosporine for anal furunculosis in dogs

Twenty-four dogs with anal furunculosis were treated with cyclosporine once daily for 13 weeks at dosages of 1.5, 3.0, 5.0 or 7.5 mg/kg, and re-examined after six and 12 months. After 13 weeks the disease in six of the dogs was in remission, 11 were controlled or improved and seven had failed to respond. The response of the dogs given the highest dose was significantly better than the response of the other groups taken together (P < 0.014), and better than the responses of the groups given 1.5 mg/kg and 5 mg/kg (P < 0.05). The dogs improved clinically during the treatment, most rapidly during the first five weeks. Of the six dogs that were in remission after 13 weeks, three relapsed after one, two and six months. The 11 dogs that were improved or controlled after 13 weeks were either left untreated or were continued on cyclosporine medication for one to three months at a dosage of 1.5 to 7.5 mg/kg; the disease went into remission in four cases and remained controlled in the other seven, but four of the 11 cases relapsed during the 12 months following the treatment. The side effects observed included increased coat turnover and transient vomiting.     

High versus low protein diets to mink--postprandial plasma urea and creatinine response, osmotic load and pattern of nitrogen and electrolyte excretion.

Nitrogen balance, pattern of excretion of nitrogenous end-products, endogenous urinary N excretion, postprandial plasma urea and creatinine, osmotic load, urinary electrolyte excretion and water intake/output relationships were studied in 12 adult female mink fed a high protein diet (HP; n = 6) providing about 155 g protein/kg or a low protein diet (LP; n = 6) providing about 95 g protein/kg. Two balance periods of each 3 d were used and diets were fed raw or cooked. After the last balance period followed a 48 h fasting period. Postprandial plasma urea and creatinine were studied for 48 h following a test meal given after an overnight fast. Osmotic load was determined based on collection of non-acidified urine carried out during 48 h. Level of protein supply did not affect N balance, being close to zero, whereas slightly negative balances were achieved for fasting animals. Protein supply was clearly reflected in excretion of urinary urea and allantoin but not in creatinine and uric acid. Endogenous urinary N excretion was estimated by a second order regression equation giving an intercept of 280 mg/kg0.75. Post-prandial plasma urea concentrations were strongly influenced by protein supply, HP animals having substantially higher peaks than LP animals, but values returned to fasting values within 24 h after the test meal. Plasma creatinine followed a biphasic pattern with a peak about 2 h after feeding and a nadir approximately 6 h after feeding. Physical form of diet influenced postprandial urea, animals fed raw diets having a higher peak, but not creatinine. The HP diet provided almost the double osmotic load of the LP diet and a corresponding increase in urine volume. The resulting water balances were identical irrespective of diet, showing that water intake/output relationships are very accurately regulated.     

Effects of different rates of drying cassava root on its toxicity to broiler chicks.

1. The effects of drying cassava root at different rates on its composition and toxicity to broiler chicks were examined. Unpeeled roots from a high-cyanide cultivar of cassava were chipped and dried at 25 degrees C to a moisture content of below 100 g/kg over 24 h for fast-dried meal (FD) or 72 h for slow-dried meal (SD). The meals were incorporated at 250 and 500 g/kg into semi-synthetic diets which were fed to day-old broiler chicks as mash or pellets in separate experiments. 2. The two drying rates produced meals with similar concentrations of polyphenols, but different concentrations of cyanogens, the latter being 38 and 482 mg total cyanide/kg for SD and FD, respectively. The linamarin, acetonecyanohydrin or total cyanide content measurements of pelleted diets were highly correlated. 3. Growth rates of chicks fed on SD-based diets were significantly higher than those of chicks fed on FD-based diets. Compared with a control diet, weight gain of chicks fed on the 500 g FD/kg diet (containing 258 mg total cyanide/kg) was 77% lower, although performance also appeared to be reduced at 142 mg total cyanide/kg. 4. The ratio of water:food intake of chicks was higher in FD than in SD groups, and this was reflected in the high water content of excreta. There was increased bile excretion, the chloretic effect increasing with the cyanogen content of diet. Pancreas weights were lower in FD than in SD groups in experiment 1 (mash diets), but not in experiment 2 (pelleted diets), while there was a significant interaction between drying method and cassava inclusion rate on liver weight in experiment 2, but not in experiment 1. There were no effects on the mortality rate. 5. Pelleting of diets generated high temperatures, but did not significantly alter the cyanogen concentration or the growth of the chicks. 6. Thus, slower rates of drying cassava roots produce meals with lower cyanogen concentration that are, consequently, less toxic to broiler chicks. Cassava root meal of less than 40 mg total cyanide/kg can be fed to broiler chicks at 500 g/kg without any adverse effects.     

Effect of Escherichia coli endotoxin on tissue lipoprotein lipase activities in chickens

1. Four-week-old broiler chickens were injected intravenously with from 0.01 to 1 mg of E. coli endotoxin/kg body weight or with saline. 2. At all doses used endotoxin markedly depressed food intake and lipoprotein lipase activities in muscle and adipose tissue within 8 h. Heart lipoprotein lipase activity was significantly depressed only at doses of 0.1 mg endotoxin/kg body weight or greater. 3. Treatment of birds with 0.3 mg endotoxin/kg body weight reduced post-heparin lipoprotein lipase activity to 0.13 of that in control birds in 8 h. 4. Endotoxin generally depressed plasma very-low-density lipoprotein concentration. Plasma non-esterified fatty acid concentration was significantly elevated only in birds given 1 mg endotoxin/kg body weight. 5. Fatty acid synthetase activity in the liver of endotoxin-treated birds was significantly lower than in control birds 16 h after administration of endoxin, but not after 8 h. 6. These results show that tissue lipoprotein lipase activity in birds is very responsive to E. coli endotoxin, as in mammals. Hypertriglyceridaemia occurs only occasionally in endotoxin-treated chickens, most probably because of the particularly close relationship between food intake and hepatic lipoprotein synthesis in birds.     

Evaluation of the effect of cephalexin and enrofloxacin on clinical laboratory measurements of urine glucose in dogs

OBJECTIVE: To determine the effects of cephalexin and enrofloxacin on results of 4 commercially available urine glucose tests in dogs. ANIMALS: 6 healthy adult female dogs. PROCEDURE: In a crossover design, cephalexin (22 and 44 mg/kg [10 and 20 mg/lb], p.o., q 8 h) or enrofloxacin (5 and 10 mg/kg [2.3 and 4.5 mg/lb], p.o., q 12 h) was administered to dogs for 1 day. Urine samples were tested for glucose at 0, 6, and 24 hours after drug administration. In vitro, dextrose was added to pooled glucose-negative canine urine samples containing either no antimicrobial or known concentrations of either antimicrobial; urine samples were then tested for glucose. RESULTS: In vivo, false-positive results were obtained by use of a tablet test in the presence of both antimicrobials and by use of a strip test in the presence of cephalexin. In vitro, false-positive results were obtained with the tablet test at the highest urine concentration of cephalexin (2,400 microg/mL) and with a strip test at the highest concentration of enrofloxacin (600 microg/mL). Enrofloxacin in urine samples containing dextrose caused the urine glucose tests to underestimate urine glucose concentration. CONCLUSIONS AND CLINICAL RELEVANCE: Cephalexin and enrofloxacin at dosages used in clinical practice may result in false-positive or false-negative urine glucose results, and care should be taken when using urine as a basis for identifying or monitoring diabetic animals.